MedTrace Logo

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-04-22

No results posted yet for this study

Summary

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

Conditions

  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

DRUG

ADX-038

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Sponsors & Collaborators

  • ADARx Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Donald Fong, MD · ADARx Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-10
Primary Completion
2030-02-28
Completion
2030-08-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06990269 on ClinicalTrials.gov